Submit a comment

A requirement for the rac1 GTPase in the signal transduction pathway leading to cardiac myocyte hypertrophy.
J B Pracyk, … , K Irani, T Finkel
J B Pracyk, … , K Irani, T Finkel
Published September 1, 1998
Citation Information: J Clin Invest. 1998;102(5):929-937. https://doi.org/10.1172/JCI2552.
View: Text | PDF
Research Article

A requirement for the rac1 GTPase in the signal transduction pathway leading to cardiac myocyte hypertrophy.

Abstract

We have used adenoviral-mediated gene transfer of a constitutively active (V12rac1) and dominant negative (N17rac1) isoform of rac1 to assess the role of this small GTPase in cardiac myocyte hypertrophy. Expression of V12rac1 in neonatal cardiac myocytes results in sarcomeric reorganization and an increase in cell size that is indistinguishable from ligand-stimulated hypertrophy. In addition, V12rac1 expression leads to an increase in atrial natriuretic peptide secretion. In contrast, expression of N17rac1, but not a truncated form of Raf-1, attenuated the morphological hypertrophy associated with phenylephrine stimulation. Consistent with the observed effects on morphology, expression of V12rac1 resulted in an increase in new protein synthesis, while N17rac1 expression inhibited phenylephrine-induced leucine incorporation. These results suggest rac1 is an essential element of the signaling pathway leading to cardiac myocyte hypertrophy.

Authors

J B Pracyk, K Tanaka, D D Hegland, K S Kim, R Sethi, I I Rovira, D R Blazina, L Lee, J T Bruder, I Kovesdi, P J Goldshmidt-Clermont, K Irani, T Finkel

×

Guidelines

The Editorial Board will only consider comments that are deemed relevant and of interest to readers. The Journal will not post data that have not been subjected to peer review; or a comment that is essentially a reiteration of another comment.

  • Comments appear on the Journal’s website and are linked from the original article’s web page.
  • Authors are notified by email if their comments are posted.
  • The Journal reserves the right to edit comments for length and clarity.
  • No appeals will be considered.
  • Comments are not indexed in PubMed.

Specific requirements

  • Maximum length, 400 words
  • Entered as plain text or HTML
  • Author’s name and email address, to be posted with the comment
  • Declaration of all potential conflicts of interest (even if these are not ultimately posted); see the Journal’s conflict-of-interest policy
  • Comments may not include figures
This field is required
This field is required
This field is required
This field is required
This field is required
This field is required
Rich Text Editor, eletter_body